The Reporting Persons purchased the securities of the Issuer reported herein based on the Reporting Persons' belief that the securities, when purchased, represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Issuer at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of securities of the Issuer on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. On November 24, 2025, the Radoff Foundation and Mr. Radoff entered into a securities purchase agreement (the "Purchase Agreement") with the Issuer and certain other investors pursuant to which the Issuer agreed to issue and sell an aggregate of: (i) 2,221,141 Shares, and (ii) warrants (the "Common Warrants") to purchase up to 1,029,104 Shares (the "Warrant Shares") in a private placement offering of the Issuer's securities (the "Offering"). The price of the Shares sold in the Offering was $1.10 per Share and each investor (other than certain investors affiliated with the Issuer) received one Common Warrant for every two Shares purchased in the Offering. Pursuant to the Offering, (x) the Radoff Foundation purchased an aggregate of 560,090 Shares and Common Warrants to purchase up to an aggregate of 280,045 Warrant Shares and (y) Mr. Radoff purchased an aggregate of 560,091 Shares and Common Warrants to purchase up to an aggregate of 280,045 Warrant Shares. The Common Warrants have an exercise price of $1.65 per Share (the "Exercise Price"), and can be exercised starting 180 days following the date of closing of the Offering (the "Initial Exercise Date") and will be exercisable for three years following the Initial Exercise Date (the "Termination Date"). The Common Warrants contain customary anti-dilution provisions in respect of recapitalizations, stock splits, stock dividends and similar transactions but do not contain anti-dilution provisions with respect to future securities issuances. Beginning on the Initial Exercise Date and ending on the Termination Date, the Issuer will have the right to require holders of Common Warrants to exercise their Common Warrants, in whole or in part, under certain circumstances and subject to certain conditions, if the price of the Shares exceeds two times the then-current Exercise Price of the Common Warrants for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period. The Offering closed (the "Closing") on November 28, 2025. Pursuant to the terms of the Purchase Agreement, following the Closing, Mr. Radoff has the right, but not the obligation, to request that the Board appoint one individual as a director to the Board, subject to certain customary eligibility requirements. Mr. Radoff has recommended that Joshua Schecter serve as a director to the Board, and it is expected that Mr. Schecter will join the Board following the Closing. The Purchase Agreement provides that the Issuer will register the resale of the Shares and the Warrant Shares acquired in connection with the Offering. The Issuer is required to prepare and file a registration statement with the Securities and Exchange Commission no later than 45 days after the date of the Closing (the "Filing Deadline"). The Issuer is required to use its commercially reasonable efforts to have the registration statement declared effective no later than the 30th calendar day following the Filing Deadline or if the Securities and Exchange Commission notifies the Issuer that it will "review" the initial registration statement, the 75th calendar day following the Filing Deadline. The Reporting Persons disclaim the formation of any group with the other investors that are parties to the Purchase Agreement in all respects. The foregoing descriptions of the terms of the Purchase Agreement and the Common Warrants herein are not intended to be complete and are qualified in their entirety by reference to copies of the form of Purchase Agreement and the form of Common Warrant, which are attached hereto as Exhibits 99.1 and 99.2, respectively. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the securities of the Issuer, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in additional communications with management and the Board of Directors (the "Board") of the Issuer, engaging in discussions with stockholders of the Issuer or third parties, including potential acquirers and service providers about the Issuer and the Reporting Persons' investment, making proposals to the Issuer concerning changes to the capital allocation strategy, capitalization, ownership structure, including a sale of the Issuer as a whole or in parts, Board structure (including Board composition) or operations of the Issuer, purchasing additional securities of the Issuer, selling some or all of their securities, engaging in short selling of or any hedging or similar transaction with respect to the securities of the Issuer, or changing their intention with respect to any and all matters referred to in Item 4.